Publication:
Intravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous.

Simple item page
dc.contributor.authorOzsutcu, Mustafa
dc.contributor.authorGulkilik, Gokhan
dc.contributor.authorAyintap, Emre
dc.contributor.authorAltinisik, Muhammed
dc.contributor.authorDemirci, Goktug
dc.contributor.authorAras, Cengiz
dc.date.accessioned2023-05-16T16:56:24Z
dc.date.available2023-05-16T16:56:24Z
dc.date.issued2012-12-31T22:00:00Z
dc.description.abstractTo report 2 eyes of a patient which developed vitreomacular traction (VMT) 1 month after intravitreal bevacizumab (IVB) injection.
dc.description.abstractA 45-year-old female with bilateral diffuse diabetic macular edema (DME) received bilateral IVB.
dc.description.abstractHer initial visual acuity (VA) was 0.15 and 0.2 in OD and OS, respectively. Central foveal thickness (CFT) was 568 and 662 µm in OD and OS, respectively, without any sign of VMT. Both eyes responded well initially but developed VMT at 1 month. This time, intravitreal triamcinolone (IVTA) injection was performed. One month after IVTA injection, VMT was released and CFT decreased to 163 and 181 µm in OD and OS, respectively. Six months after IVTA injection, CFT was 163 and 153 µm, and VA was 0.7 and 0.9 in OD and OS, respectively.
dc.description.abstractIn eyes with DME and attached posterior vitreous, VMT may develop after IVB injection and increase edema. IVTA injection might be an option to release VMT before considering vitrectomy.
dc.identifier.pubmed23467022
dc.identifier.urihttps://hdl.handle.net/20.500.12645/38247
dc.language.isoen
dc.subjectBevacizumab
dc.subjectDiabetic macular edema
dc.subjectPosterior vitreous
dc.subjectVitreomacular traction
dc.titleIntravitreal bevacizumab may increase diabetic macular edema in eyes with attached posterior vitreous.
dspace.entity.typePublication
Files
Collections
Pubmed Ek Yayınlar